IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.
about
Influence of immunoglobulin isotype on therapeutic antibody functionSynergistic activation of innate and adaptive immune mechanisms in the treatment of gonadotropin-sensitive tumorsFractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour ResponseBiological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificitySialyl-tn in cancer: (how) did we miss the target?Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice.Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes.Effect of an anti-human Co-029/tspan8 mouse monoclonal antibody on tumor growth in a nude mouse model.Anti-idiotype immunization of cancer patients: modulation of the immune responseComplete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.A novel and effective cancer immunotherapy mouse model using antigen-specific B cells selected in vitroUnarmed, tumor-specific monoclonal antibody effectively treats brain tumorsm17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancerMacrophages are critical effectors of antibody therapies for cancerAntibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy.The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapyExpression of an antigen homologous to the human CO17-1A/GA733 colon cancer antigen in animal tissues.Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.Epitope- and antigen-specific cancer vaccines.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.Monoclonal antibodies that prevent adhesion of B 16 melanoma cells and reduce metastases in mice: crossreaction with human tumor cells.Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysisIsolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants.Cancer Immunotherapy: Whence and Whither.CD48 as a novel molecular target for antibody therapy in multiple myeloma.Tumor detection using radiolabeled monoclonal antibodies.The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine modelHuman monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo.Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion moleculeDifferential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock.Concepts of antibody-mediated cancer therapy.Cytotoxicity induced by monoclonal antibody to alpha-fetoprotein coadministered with spleen cells of nude mice.
P2860
Q26772080-C6323569-86B9-412E-B78F-3450C03817E7Q27324860-4E8AE9F6-2D1C-41FC-BA07-0E086D8DAFB1Q27334088-23B807B6-22B2-46A2-B77C-B845BDAE8878Q33586088-80CB18AB-DBFE-46CC-98F9-FD9A57AC8F29Q33649572-DAEC5E17-1A4A-45CA-8884-EF6EE554C50FQ33751822-CB1EE3C1-16C4-4540-8735-AEE86F582F3BQ33821962-A3CBDF39-A9B3-41FD-B571-34FA83FE6F6EQ34211752-3876F318-0380-4937-96AF-A82EC274FF27Q34366216-6AF57665-F018-4983-BD77-D4BBA9011681Q34624590-643963E5-9123-421F-B8F0-3463EE028C18Q34695471-D30C1064-5022-494F-8906-1E120396D782Q35125204-D79C6F3F-4ED1-4481-BE53-B702AF8B0954Q35162055-D8AEC4DC-E27D-4D0A-865C-B60D29B13298Q36079704-B9824DAB-97D4-4BDC-94A5-705F31ECBBD3Q36213288-1194909E-A79F-4653-BCD4-2CBA54896A23Q36228329-5041A95F-10C8-4EDD-8F91-E4198C0659A0Q36245704-7C8481C9-8D84-4D04-AD38-858F956F9489Q36270135-DE8EB2E4-BD55-4A13-853A-3C6BC9AE345AQ36399234-AAB4A014-4EA2-4D40-8849-98B2B2AEFC14Q36402637-5AF4E79A-A3C8-4389-A682-3FF2765210C9Q36431169-46D33E10-8BB8-4224-B87A-6F8878B56229Q36659424-C2D8AB4C-AC98-46EC-B588-61899AAB2BCAQ36801560-9B6B8011-B0D1-4583-AB30-9E0B9031116FQ36930069-30823966-2110-46C2-9FDD-AC6FFD29B243Q37174938-4AACE5B2-B612-4C70-BF8C-6D139FC8EDC8Q37348039-4476B76D-D16E-42A7-A39C-356330060360Q37511394-50CABD1B-4354-4D70-9166-EA444B50F305Q37526231-95E9C8EB-4F3B-4EC0-B3A7-54677A3ADB71Q37558378-FE6282C5-DB9E-4564-AA52-1BBD63B1078AQ38737924-4553173D-5632-48FB-BCCA-55C649FED946Q39440638-207BCD6B-BEC5-48E8-A108-D03448AAA0E6Q39689840-E6DC4CB6-E6EA-459D-BEA4-7E48A60F85D8Q39708585-1D3A6DA3-60C4-4644-91C8-C8EE6AAB12CAQ39852463-A0E74CE4-F9A8-458F-A8AE-602CBC37A46DQ40332957-57B006D2-768E-488E-9181-DF2C83229B2AQ40379395-F45E9979-4220-417C-82EF-BC330252E548Q40661240-7717DCA7-A51F-4E03-9CBE-53C3889A180EQ40703896-5BE95A0E-1697-4C75-BE20-166940008B3BQ40891323-FE9F769A-4F96-49DF-8975-8353D9B7CF2DQ41587849-B3F540AD-C6BC-43A8-88A0-9969F20797B7
P2860
IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
1982年學術文章
@zh
1982年學術文章
@zh-hant
name
IgG2a monoclonal antibodies in ...... teraction with effector cells.
@ast
IgG2a monoclonal antibodies in ...... teraction with effector cells.
@en
type
label
IgG2a monoclonal antibodies in ...... teraction with effector cells.
@ast
IgG2a monoclonal antibodies in ...... teraction with effector cells.
@en
prefLabel
IgG2a monoclonal antibodies in ...... teraction with effector cells.
@ast
IgG2a monoclonal antibodies in ...... teraction with effector cells.
@en
P2860
P356
P1476
IgG2a monoclonal antibodies in ...... teraction with effector cells.
@en
P2093
P2860
P304
P356
10.1073/PNAS.79.15.4761
P407
P577
1982-08-01T00:00:00Z